#Asundexian
LightNews LightNews
med-iqcardiology.bsky.social
17/What other clinical trials for FXI/XIa inhibitors are in progress?
Ongoing phase 3 trials include the following studies for abelacimab: LILAC-TIMI 76 comparing abelacimab versus placebo in AF not eligible for OAC; ASTER comparing abelacimab versus apixaban for cancer-associated VTE; MAGNOLIA comparing abelacimab versus LMWH for GI cancer-associated VTE. The following studies for milvexian are ongoing: LIBREXIA-AF comparing milvexian 100 BID versus apixaban; LIBREXIA-STROKE comparing milvexian 25 BID versus placebo for recent non-AF stroke. The OCEANIC- STROKE study is comparing asundexian 50 daily versus placebo for recent non-AF stroke. The LIBREXIA-ACS study comparing milvexian 25 mg BID versus placebo for recent ACS was stopped in November 2025.
January 14, 2026 at 8:10 PM
med-iqcardiology.bsky.social
12/Results for OCEANIC-AF (asundexian phase 3):

🔹Terminated early—rate of stroke and SE were higher in asundexian arm vs apixaban arm
🔹ISTH major bleeding scores were lower in asundexian arm
A figure shows the OCEANIC-AF study design that included patients with AF who were given either asundexian at 50 mg daily or apixaban 5 mg twice daily. The efficacy outcome was prevention of stroke and systemic embolism. The safety outcome was major bleeding events. A bar graph shows the efficacy and safety results. Stroke or systemic embolism occurred in 1.3% of patients taking asundexian and in 0.4% of patients taking apixaban with an HR of 3.79 and a 95% CI of 2.46 to 5.83. Major bleeding occurred in 0.2% of patients taking asundexian and in 0.7% of patients taking apixaban with an HR of 0.32 and a 95% CI of 0.18 to 0.55.
January 14, 2026 at 8:10 PM
med-iqcardiology.bsky.social
10/Which clinical studies have investigated FXI/XIa inhibitor therapy in patients with AF so far?

🔹Abelacimab phase 2 AZALEA-TIMI 71
🔹Asundexian phase 3 OCEANIC-AF
January 14, 2026 at 8:10 PM
med-iqcardiology.bsky.social
9/Findings from a meta-analysis of patients undergoing knee arthroplasty:

🔹41% reduction in VTE with an FXI inhibitor
🔹59% reduction in bleeding risk with an FXI inhibitor
🔹Asundexian was not included
A figure shows the meta-analysis results for phase 2 studies in knee arthroplasty that included IONIS-FIXI-Rx, osocimab, abelacimab, and milvexian. The risk ratios favor factor XI inhibitors over low-molecular-weight heparin for reductions in venous thromboembolism and clinically relevant bleeding.
January 14, 2026 at 8:10 PM
med-iqcardiology.bsky.social
8/The following investigational FXI/XIa inhibitors are currently in clinical trials; none have been approved yet for use in the US or Europe.
Current factor XI/XIa drugs include monoclonal antibody abelacimab given once a month. Small molecule inhibitors include asundexian given once a day and milvexian given twice a day.
January 14, 2026 at 8:10 PM
befast.bsky.social
October: Redemption of the FXIa Class

At #WSC2025, OCEANIC-STROKE provided a major win the class desperately needed. Unlike the AF trial, asundexian in secondary prevention hit its mark. We're all eagerly awaiting the full publication.
December 17, 2025 at 9:02 PM
drtimos.bsky.social
Signal or noise? > Asundexian Identified as Potential Option for Reducing
Ischemic Stroke Recurrence with Lower Bleeding Risk -
geneonline.com >> Comment below! #strategy #competitiveintelligence #marketing #pharma #competitivemarketing #healthcare #biotech #pharmaceutical
Asundexian Identified as Potential Option for Reducing Ischemic Stroke Recurrence with Lower Bleeding Risk - geneonline.com
Asundexian Identified as Potential Option for Reducing Ischemic Stroke Recurrence with Lower Bleeding Risk  geneonline.com
dlvr.it
December 10, 2025 at 6:30 PM
boersenfuchs.bsky.social
Bayer (BAYN.DE) zeigt R&D-tempo via asundexian; FCF und ROIC bleiben gedrückt wegen. https://www.wsj.com/health/pharma/bayer-sees-positive-results-in-study-for-asundexian-as-stroke-treatment-6ad4e3c0?gaa_at=eafs&gaa_n=AWEtsqfMBcZjnZXH9S2m7X_5iiY3EcTfVcnYN6RRiMRS93Wcm6E2gr_c_pEf&gaa_ts=692e9700&gaa_s
December 2, 2025 at 1:06 PM
boersenfuchs.bsky.social
Analyst: Bayer shows R&D tempo boost from asundexian; ROIC weak, FCF pressured by glyphosate reserves (€1bn+) and CAPEX. Watch regulatory orchestration. See $BAYRY and BAYN.DE
December 2, 2025 at 7:06 AM
boersenfuchs.bsky.social
Als EU-Analyst sehe ich Bayer $BAYRY und BAYN.DE: Asundexian beflügelt F&E, doch ROIC tief, FCF. https://www.wsj.com/health/pharma/bayer-sees-positive-results-in-study-for-asundexian-as-stroke-treatment-6ad4e3c0?
December 1, 2025 at 1:07 PM
herzmedizin.bsky.social
🔬 #Studienkompakt – Must-know für Kardiologen💡
🐟 PISCES: Kardioprotektion durch Fischöl
💻 PREVENT: Online-Tool für 30-Jahres-Risiko
🧠 OCEANIC-STROKE: Asundexian erfolgreich
…und viele weitere Studien:
➡️ herzmedizin.de/fuer-...
#Herzmedizinde #DGK #CardioSky
Studien kompakt: 26.11.2025
Überblick zu aktuellen Studien u. a. zu Fischöl, Hypertonie durch chronische Schmerzen, GLP1-RA bei HFpEF und Schlaganfallprävention mit Asundexian.
herzmedizin.de
November 28, 2025 at 2:33 PM
gendronn.bsky.social
🧐Interesting… #Asundexian was not effective in #AF, but OCEANIC-STROKE shows its superiority when combined with antiplatelet therapy, demonstrating a reduction in ischemic #stroke in patients with non-cardioembolic ischemic stroke or high-risk TIA, compared to placebo plus antiplatelet therapy.
#FXI
www.bayer.com
November 28, 2025 at 12:38 AM
dgk-org.bsky.social
🔬 #Studienkompakt – Must-know für Kardiologen💡
🐟 PISCES: Kardioprotektion durch Fischöl
💻 PREVENT: Online-Tool für 30-Jahres-Risiko
🧠 OCEANIC-STROKE: Asundexian erfolgreich
…und viele weitere Studien:
➡️ herzmedizin.de/fuer-...
#Herzmedizinde #DGK #Cardiosky #Kardiologie
November 27, 2025 at 7:46 AM
a-reader-ft.bsky.social
Bayer soars on promising trial results for stroke prevention drug—Bayer said asundexian has been granted fast track designation by the US Food and Drug Administration as a potential treatment for stroke prevention, which could… www.ft.com/content/ff8c... Aanu Adeoye @financialtimes.com
Bayer soars on promising trial results for stroke prevention drug
Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges
www.ft.com
November 27, 2025 at 2:23 AM
yoshitakahoshi.bsky.social
Bayer’s FXIa inhibitor asundexian meets primary endpoints in the Phase 3 OCEANIC-STROKE trial.

🔗 Full article: stellanews.life/technology_c...
FXIa阻害薬アスンデキサン、脳卒中再発予防で第3相試験成功 虚血性脳卒中リスクを有意に低減し、大出血リスクを増加させず | STELLANEWS.LIFE
アスンデキサンが第3相試験で二次脳卒中予防に成功。虚血性脳卒中リスクを有意に低減し、大出血リスクを増加させなかった初のFXIa阻害薬として注目。
stellanews.life
November 24, 2025 at 9:26 PM
tctmd.bsky.social
Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE
Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE
Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE cmacahilig@crf.org Mon, 11/24/2025 - 13:50 Michael O'Riordan The top-line results are good news for asundexian after disappointment in the AF setting.
www.tctmd.com
November 24, 2025 at 6:59 PM
notreload.bsky.social
$BMY +3.8% [Bayer's asundexian succeeds in Phase 3 stroke prevention trial, becoming first FXIa inhibitor to show positive results and potentially opening door for safer blood clot medications.] notreload.xyz/bayer-stroke...
Bayer's Stroke Drug Succeeds in Phase 3 Trial, Stock Jumps
Bayer's asundexian succeeds in Phase 3 stroke prevention trial, becoming first FXIa inhibitor to show positive results and potentially opening door for safer blood clot medications.
notreload.xyz
November 24, 2025 at 3:07 PM
pharmaphorum.bsky.social
Prospects for #Bayer's oral #FactorXIainhibitor asundexian were looking speculative when it failed a phase 3 trial in atrial fibrillation (AF), but new data in secondary #strokeprevention could get the programme back on track.
Stroke data breathes life back into Bayer's asundexian
Prospects for Bayer's oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.
buff.ly
November 24, 2025 at 2:00 PM
de-nachrichten.bsky.social
Bayer hat mit Asundexian einen wichtigen Erfolg erzielt. Die Phase-III-Studie OCEANIC-STROKE erreichte sowohl den Wirksamkeits- als auch den Sicherheitsendpunkt.
BAYER bringt Milliardenblockbuster auf die Zielgerade
stock3.com
November 24, 2025 at 12:28 PM
ftaonline.com
Segnali positivi da asundexian contro le recidive dell'ictus. Il titolo supera ostacoli che testava da mesi, ma già a fine luglio il gruppo aveva alzato la guidance

🇮🇹 #italia #finanza #notizie #mercati #borsa #investire #portafoglio
Bayer, l'azione strappa al rialzo, ecco cosa è successo al big pharma tedesco
Segnali positivi da asundexian contro le recidive dell'ictus. Il titolo supera ostacoli che testava da mesi, ma già a fine luglio il gruppo aveva alzato la guidance
www.ftaonline.com
November 24, 2025 at 12:10 PM
wirtschaftswoche.bsky.social
Etwa zwei Jahre nach dem Rückschlag in der Forschung zum Gerinnungshemmer Asundexian berichtet Bayer nun über positive Studienergebnisse mit dem Wirkstoff.
Gerinnungshemmer: Erfolg zwei Jahre nach Rückschlag – Bayer meldet positive Studienergebnisse mit Asundexian
Etwa zwei Jahre nach dem Rückschlag in der Forschung zum Gerinnungshemmer Asundexian berichtet Bayer nun über positive Studienergebnisse mit dem Wirkstoff.
www.wiwo.de
November 24, 2025 at 7:44 AM
vjneurology.bsky.social
Want to hear about the OCEANIC-STROKE trial investigating asundexian as secondary #stroke prevention in participants who have had an acute ischemic stroke or high-risk transient ischemic attack?

Watch our interview with Mike Sharma from #WSC2025:

🎥 buff.ly/pkZ0w6z

#Neurology #MedSky
November 3, 2025 at 10:00 AM
fingraph.bsky.social
在经历了数年的低迷后，德国拜耳公司的股价在2025年强势反弹。今年以来，该公司股价已飙升约40%，成为德国DAX指数中表现最好的成份股之一。市场乐观情绪主要源于两大催化剂：一是投资者押注其在美国关于“农达”（Roundup）除草剂的长期法律诉讼可能取得突破；二是对其预防中风的实验性新药Asundexian寄予厚望。尽管股价仍远低于历史高位且面临高额债务等挑战，但投资者对其困境反转的预期正日益增强。
来源：#Bloomberg
June 19, 2025 at 12:49 PM
librariancapital.bsky.social
"Bayer’s $BAYN Stock Is Charting a 40% Rebound After Years of Losses" (Bloomberg)

"Traders are betting on a possible breakthrough in Bayer’s long-running legal battle over Roundup weedkiller and that its experimental Asundexian drug might be a blockbuster"
www.bloomberg.com/news/article...
June 18, 2025 at 8:33 AM
markgoldbergmd.bsky.social
OCEANIC-AF #stroke trial: 14,810 patients with high-risk atrial fibrillation. Trial was stopped because of 3.8x more strokes (but less bleeding) in group receiving factor X1a inhibitor asundexian compared to standard direct oral anticoagulant apixiban.

www.nejm.org/doi/10.1056
Graphs from OCEANIC-AF clinical trial. Top figure shows 3.8x higher risk of stroke or embolism in group receiving asundexian compared to apixaban at one year. Major bleeding: 0.2% compared to 0.7%. Any adverse event: 34.9% compared to 34.9%. (In stroke research, AF is an abbreviation for atrial fibrillation.)
January 27, 2025 at 10:21 PM